Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
Exclusions
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Remdesivir  COVID-19 treatment studies for Remdesivir  C19 studies: Remdesivir  Remdesivir   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)
Other Treatments Global Adoption
Outcomes in COVID-19 remdesivir studies
Home   
Share  
Tweet
  StudiesStudies
  Global AdoptionAdoption
  Submit FeedbackFeedback
Outcomes in remdesivir studies. Studies show significantly increased risk of acute kidney injury.
All studies   Exclusions   Mortality   Ventilation   ICU   Hospitalization   Serious outcomes   Recovery   Viral clearance   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies 17% 36 123,330 Improvement, Studies, Patients Relative Risk Mortality 19% 33 122,149 Ventilation -24% 7 32,601 ICU admission -34% 2 2,163 Hospitalization -39% 2 2,486 Recovery 24% 2 1,188 Viral clearance 0% 1 142 RCTs 13% 8 8,887 RCT mortality 8% 7 8,325 Peer-reviewed 12% 29 112,330 Early 76% 2 934 Late 16% 35 122,768 Remdesivir for COVID-19 c19rmd.com May 2022 Favorsremdesivir Favorscontrol after exclusions
0 0.5 1 1.5+ ALL STUDIES MORTALITY VENTILATION ICU ADMISSION HOSPITALIZATION RECOVERY VIRAL CLEARANCE RCTS RCT MORTALITY PEER-REVIEWED After Exclusions ALL STUDIES All Early Late Remdesivir for COVID-19 C19RMD.COM MAY 2022
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Madan (ES) 66% 0.34 [0.12-0.96] death 4/112 27/260 Improvement, RR [CI] Treatment Control Gottlieb (DB RCT) 87% 0.13 [0.03-0.59] death/hosp. 2/279 15/283 Tau​2​ = 0.06, I​2​ = 11.9%, p = 0.0025 Early treatment 76% 0.24 [0.10-0.61] 6/391 42/543 76% improvement Wang (RCT) -9% 1.09 [0.54-2.18] death 22/158 10/78 Improvement, RR [CI] Treatment Control Olender 59% 0.41 [0.24-0.71] death 24/312 102/818 Spinner (RCT) 35% 0.65 [0.18-2.40] death 5/384 4/200 Pasquini (ICU) 16% 0.84 [0.69-0.94] death 14/25 24/26 ICU patients Fried 61% 0.39 [0.15-0.99] death 4/48 2,510/11,673 Beigel (RCT) 27% 0.73 [0.52-1.03] death 541 (n) 521 (n) SOLIDARITY (RCT) 5% 0.95 [0.81-1.11] death 301/2,743 303/2,708 Solh 47% 0.53 [0.39-0.70] death 63/219 202/424 Flisiak 49% 0.51 [0.19-1.30] death 5/122 17/211 Garibaldi 20% 0.80 [0.46-1.41] death 23/303 45/303 Ullah -100% 2.00 [0.67-5.94] death 8/30 4/30 Yeramaneni -24% 1.24 [0.11-14.2] death 32 (n) 7,126 (n) Goldberg 9% 0.91 [0.50-1.67] hosp. time 29 (n) 113 (n) Tsuzuki -4% 1.04 [0.98-1.09] death 69/824 285/11,663 Mahajan (RCT) -76% 1.76 [0.46-6.82] death 5/34 3/36 Mulhem -86% 1.86 [0.21-5.24] death 1/8 515/3,211 Aghajani 19% 0.81 [0.46-1.46] death 46 (n) 945 (n) Elhadi (ICU) -11% 1.11 [0.81-1.51] death 14/21 267/444 ICU patients Pourhoseingholi -2% 1.02 [0.72-1.44] death 42/123 297/2,345 Arch (PSM) 20% 0.80 [0.64-0.98] death 203/1,491 777/4,676 Barrat-Due (DB RCT) 0% 1.00 [0.20-4.60] death 3/37 4/53 Ohl (PSM) -6% 1.06 [0.83-1.36] death 143/1,172 124/1,172 Madan 44% 0.56 [0.33-0.95] death 23/398 27/260 Kuno (PSM) 1% 0.99 [0.84-1.17] death 214/999 216/999 Diaz 35% 0.65 [0.46-0.92] death 33/286 173/852 Ader (RCT) 6% 0.94 [0.59-1.45] death 34/414 37/418 Mozaffari 12% 0.88 [0.81-0.96] death 4,441/28,855 5,499/28,855 Schmidt (PSM) -509% 6.09 [2.71-13.7] severe case 43 (n) 434 (n) Jamir (ICU) 8% 0.92 [0.55-1.55] death 60/181 41/85 ICU patients Mustafa 33% 0.67 [0.38-1.20] death 16/200 29/244 Kurniyanto -460% 5.60 [2.32-13.5] death 7/45 12/432 Siraj 53% 0.47 [0.35-0.62] death 108/413 197/587 Salehi (ICU) 37% 0.63 [0.43-0.94] death 17/40 57/85 ICU patients Elec 19% 0.81 [0.38-1.69] death 7/38 29/127 Zangeneh (ICU) 32% 0.68 [0.45-1.01] death n/a n/a ICU patients Tau​2​ = 0.05, I​2​ = 75.6%, p = 0.0015 Late treatment 16% 0.84 [0.75-0.93] 5,909/40,614 11,810/82,154 16% improvement All studies 17% 0.83 [0.74-0.93] 5,915/41,005 11,852/82,697 17% improvement 37 remdesivir COVID-19 studies c19rmd.com May 2022 Tau​2​ = 0.05, I​2​ = 76.0%, p = 0.001 Effect extraction pre-specified(most serious outcome) Favors remdesivir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gottlieb (DB RCT) 87% 0.13 [0.03-0.59] death/hosp. 2/279 15/283 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.0064 Early treatment 87% 0.13 [0.03-0.59] 2/279 15/283 87% improvement Wang (RCT) -9% 1.09 [0.54-2.18] death 22/158 10/78 Improvement, RR [CI] Treatment Control Olender 59% 0.41 [0.24-0.71] death 24/312 102/818 Spinner (RCT) 35% 0.65 [0.18-2.40] death 5/384 4/200 Pasquini (ICU) 16% 0.84 [0.69-0.94] death 14/25 24/26 ICU patients Beigel (RCT) 27% 0.73 [0.52-1.03] death 541 (n) 521 (n) SOLIDARITY (RCT) 5% 0.95 [0.81-1.11] death 301/2,743 303/2,708 Flisiak 49% 0.51 [0.19-1.30] death 5/122 17/211 Garibaldi 20% 0.80 [0.46-1.41] death 23/303 45/303 Ullah -100% 2.00 [0.67-5.94] death 8/30 4/30 Yeramaneni -24% 1.24 [0.11-14.2] death 32 (n) 7,126 (n) Goldberg 9% 0.91 [0.50-1.67] hosp. time 29 (n) 113 (n) Tsuzuki -4% 1.04 [0.98-1.09] death 69/824 285/11,663 Mahajan (RCT) -76% 1.76 [0.46-6.82] death 5/34 3/36 Aghajani 19% 0.81 [0.46-1.46] death 46 (n) 945 (n) Pourhoseingholi -2% 1.02 [0.72-1.44] death 42/123 297/2,345 Arch (PSM) 20% 0.80 [0.64-0.98] death 203/1,491 777/4,676 Barrat-Due (DB RCT) 0% 1.00 [0.20-4.60] death 3/37 4/53 Ohl (PSM) -6% 1.06 [0.83-1.36] death 143/1,172 124/1,172 Kuno (PSM) 1% 0.99 [0.84-1.17] death 214/999 216/999 Diaz 35% 0.65 [0.46-0.92] death 33/286 173/852 Ader (RCT) 6% 0.94 [0.59-1.45] death 34/414 37/418 Mozaffari 12% 0.88 [0.81-0.96] death 4,441/28,855 5,499/28,855 Jamir (ICU) 8% 0.92 [0.55-1.55] death 60/181 41/85 ICU patients Siraj 53% 0.47 [0.35-0.62] death 108/413 197/587 Zangeneh (ICU) 32% 0.68 [0.45-1.01] death n/a n/a ICU patients Tau​2​ = 0.03, I​2​ = 66.2%, p = 0.00027 Late treatment 17% 0.83 [0.75-0.92] 5,757/39,554 8,162/64,820 17% improvement All studies 18% 0.82 [0.74-0.91] 5,759/39,833 8,177/65,103 18% improvement 26 remdesivir COVID-19 studies after exclusions c19rmd.com May 2022 Tau​2​ = 0.03, I​2​ = 67.7%, p = 0.00021 Effect extraction pre-specified(most serious outcome) Favors remdesivir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Madan (ES) 66% 0.34 [0.12-0.96] 4/112 27/260 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.041 Early treatment 66% 0.34 [0.12-0.96] 4/112 27/260 66% improvement Wang (RCT) -9% 1.09 [0.54-2.18] 22/158 10/78 Improvement, RR [CI] Treatment Control Olender 59% 0.41 [0.24-0.71] 24/312 102/818 Spinner (RCT) 35% 0.65 [0.18-2.40] 5/384 4/200 Pasquini (ICU) 16% 0.84 [0.69-0.94] 14/25 24/26 ICU patients Fried 61% 0.39 [0.15-0.99] 4/48 2,510/11,673 Beigel (RCT) 27% 0.73 [0.52-1.03] 541 (n) 521 (n) SOLIDARITY (RCT) 5% 0.95 [0.81-1.11] 301/2,743 303/2,708 Solh 47% 0.53 [0.39-0.70] 63/219 202/424 Flisiak 49% 0.51 [0.19-1.30] 5/122 17/211 Garibaldi 20% 0.80 [0.46-1.41] 23/303 45/303 Ullah -100% 2.00 [0.67-5.94] 8/30 4/30 Yeramaneni -24% 1.24 [0.11-14.2] 32 (n) 7,126 (n) Tsuzuki -4% 1.04 [0.98-1.09] 69/824 285/11,663 Mahajan (RCT) -76% 1.76 [0.46-6.82] 5/34 3/36 Mulhem -86% 1.86 [0.21-5.24] 1/8 515/3,211 Aghajani 19% 0.81 [0.46-1.46] 46 (n) 945 (n) Elhadi (ICU) -11% 1.11 [0.81-1.51] 14/21 267/444 ICU patients Pourhoseingholi -2% 1.02 [0.72-1.44] 42/123 297/2,345 Arch (PSM) 20% 0.80 [0.64-0.98] 203/1,491 777/4,676 Barrat-Due (DB RCT) 0% 1.00 [0.20-4.60] 3/37 4/53 Ohl (PSM) -6% 1.06 [0.83-1.36] 143/1,172 124/1,172 Madan 44% 0.56 [0.33-0.95] 23/398 27/260 Kuno (PSM) 1% 0.99 [0.84-1.17] 214/999 216/999 Diaz 35% 0.65 [0.46-0.92] 33/286 173/852 Ader (RCT) 6% 0.94 [0.59-1.45] 34/414 37/418 Mozaffari 12% 0.88 [0.81-0.96] 4,441/28,855 5,499/28,855 Jamir (ICU) 8% 0.92 [0.55-1.55] 60/181 41/85 ICU patients Mustafa 33% 0.67 [0.38-1.20] 16/200 29/244 Kurniyanto -460% 5.60 [2.32-13.5] 7/45 12/432 Siraj 53% 0.47 [0.35-0.62] 108/413 197/587 Salehi (ICU) 37% 0.63 [0.43-0.94] 17/40 57/85 ICU patients Elec 19% 0.81 [0.38-1.69] 7/38 29/127 Zangeneh (ICU) 32% 0.68 [0.45-1.01] n/a n/a ICU patients Tau​2​ = 0.04, I​2​ = 72.7%, p < 0.0001 Late treatment 19% 0.81 [0.73-0.90] 5,909/40,542 11,810/81,607 19% improvement All studies 19% 0.81 [0.73-0.90] 5,913/40,654 11,837/81,867 19% improvement 34 remdesivir COVID-19 mortality results c19rmd.com May 2022 Tau​2​ = 0.04, I​2​ = 72.7%, p < 0.0001 Favors remdesivir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fried -37% 1.37 [0.81-2.30] 11/48 1,956/11,673 Improvement, RR [CI] Treatment Control Ullah -250% 3.50 [0.79-15.5] 7/30 2/30 Tsuzuki 2% 0.98 [0.91-1.07] 48/824 98/11,663 Mahajan (RCT) -112% 2.12 [0.41-10.8] 4/34 2/36 Arch (PSM) -68% 1.68 [1.19-2.34] 106/1,498 153/4,602 Kuno (PSM) 0% 1.00 [0.80-1.24] 140/999 140/999 Elec 11% 0.89 [0.45-1.78] 8/38 30/127 Tau​2​ = 0.06, I​2​ = 59.8%, p = 0.12 Late treatment -24% 1.24 [0.95-1.61] 324/3,471 2,381/29,130 -24% improvement All studies -24% 1.24 [0.95-1.61] 324/3,471 2,381/29,130 -24% improvement 7 remdesivir COVID-19 mechanical ventilation results c19rmd.com May 2022 Tau​2​ = 0.06, I​2​ = 59.8%, p = 0.12 Favors remdesivir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kuno (PSM) -17% 1.17 [1.00-1.37] 260/999 222/999 Improvement, RR [CI] Treatment Control Elec -72% 1.72 [1.11-2.66] 18/38 35/127 Tau​2​ = 0.05, I​2​ = 61.8%, p = 0.11 Late treatment -34% 1.34 [0.94-1.92] 278/1,037 257/1,126 -34% improvement All studies -34% 1.34 [0.94-1.92] 278/1,037 257/1,126 -34% improvement 2 remdesivir COVID-19 ICU results c19rmd.com May 2022 Tau​2​ = 0.05, I​2​ = 61.8%, p = 0.11 Favors remdesivir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Goldberg 9% 0.91 [0.50-1.67] hosp. time 29 (n) 113 (n) Improvement, RR [CI] Treatment Control Ohl (PSM) -100% 2.00 [1.33-3.02] hosp. time 1,172 (n) 1,172 (n) Tau​2​ = 0.24, I​2​ = 77.6%, p = 0.41 Late treatment -39% 1.39 [0.64-3.01] 0/1,201 0/1,285 -39% improvement All studies -39% 1.39 [0.64-3.01] 0/1,201 0/1,285 -39% improvement 2 remdesivir COVID-19 hospitalization results c19rmd.com May 2022 Tau​2​ = 0.24, I​2​ = 77.6%, p = 0.41 Favors remdesivir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Madan (ES) 66% 0.34 [0.12-0.96] death 4/112 27/260 Improvement, RR [CI] Treatment Control Gottlieb (DB RCT) 87% 0.13 [0.03-0.59] death/hosp. 2/279 15/283 Tau​2​ = 0.06, I​2​ = 11.9%, p = 0.0025 Early treatment 76% 0.24 [0.10-0.61] 6/391 42/543 76% improvement Wang (RCT) -9% 1.09 [0.54-2.18] death 22/158 10/78 Improvement, RR [CI] Treatment Control Olender 59% 0.41 [0.24-0.71] death 24/312 102/818 Spinner (RCT) 35% 0.65 [0.18-2.40] death 5/384 4/200 Pasquini (ICU) 16% 0.84 [0.69-0.94] death 14/25 24/26 ICU patients Fried 61% 0.39 [0.15-0.99] death 4/48 2,510/11,673 Beigel (RCT) 27% 0.73 [0.52-1.03] death 541 (n) 521 (n) SOLIDARITY (RCT) 5% 0.95 [0.81-1.11] death 301/2,743 303/2,708 Solh 47% 0.53 [0.39-0.70] death 63/219 202/424 Flisiak 49% 0.51 [0.19-1.30] death 5/122 17/211 Garibaldi 20% 0.80 [0.46-1.41] death 23/303 45/303 Ullah -100% 2.00 [0.67-5.94] death 8/30 4/30 Yeramaneni -24% 1.24 [0.11-14.2] death 32 (n) 7,126 (n) Tsuzuki -4% 1.04 [0.98-1.09] death 69/824 285/11,663 Mahajan (RCT) -76% 1.76 [0.46-6.82] death 5/34 3/36 Mulhem -86% 1.86 [0.21-5.24] death 1/8 515/3,211 Aghajani 19% 0.81 [0.46-1.46] death 46 (n) 945 (n) Elhadi (ICU) -11% 1.11 [0.81-1.51] death 14/21 267/444 ICU patients Pourhoseingholi -2% 1.02 [0.72-1.44] death 42/123 297/2,345 Arch (PSM) 20% 0.80 [0.64-0.98] death 203/1,491 777/4,676 Barrat-Due (DB RCT) 0% 1.00 [0.20-4.60] death 3/37 4/53 Ohl (PSM) -6% 1.06 [0.83-1.36] death 143/1,172 124/1,172 Madan 44% 0.56 [0.33-0.95] death 23/398 27/260 Kuno (PSM) 1% 0.99 [0.84-1.17] death 214/999 216/999 Diaz 35% 0.65 [0.46-0.92] death 33/286 173/852 Ader (RCT) 6% 0.94 [0.59-1.45] death 34/414 37/418 Mozaffari 12% 0.88 [0.81-0.96] death 4,441/28,855 5,499/28,855 Schmidt (PSM) -509% 6.09 [2.71-13.7] severe case 43 (n) 434 (n) Jamir (ICU) 8% 0.92 [0.55-1.55] death 60/181 41/85 ICU patients Mustafa 33% 0.67 [0.38-1.20] death 16/200 29/244 Kurniyanto -460% 5.60 [2.32-13.5] death 7/45 12/432 Siraj 53% 0.47 [0.35-0.62] death 108/413 197/587 Salehi (ICU) 37% 0.63 [0.43-0.94] death 17/40 57/85 ICU patients Elec 19% 0.81 [0.38-1.69] death 7/38 29/127 Zangeneh (ICU) 32% 0.68 [0.45-1.01] death n/a n/a ICU patients Tau​2​ = 0.05, I​2​ = 76.4%, p = 0.0016 Late treatment 16% 0.84 [0.75-0.93] 5,909/40,585 11,810/82,041 16% improvement All studies 17% 0.83 [0.74-0.93] 5,915/40,976 11,852/82,584 17% improvement 36 remdesivir COVID-19 serious outcomes c19rmd.com May 2022 Tau​2​ = 0.05, I​2​ = 76.7%, p = 0.0011 Effect extraction pre-specified(most serious outcome) Favors remdesivir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gottlieb (DB RCT) 29% 0.71 [0.37-1.37] no recov. 43/66 45/60 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.0033 Early treatment 29% 0.71 [0.37-1.37] 43/66 45/60 29% improvement Beigel (RCT) 22% 0.78 [0.67-0.89] no recov. 541 (n) 521 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.0005 Late treatment 22% 0.78 [0.67-0.89] 0/541 0/521 22% improvement All studies 24% 0.76 [0.67-0.85] 43/607 45/581 24% improvement 2 remdesivir COVID-19 recovery results c19rmd.com May 2022 Tau​2​ = 0.00, I​2​ = 0.0%, p < 0.0001 Favors remdesivir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Goldberg 0% 1.00 [0.92-1.09] viral+ 29 (n) 113 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.98 Late treatment 0% 1.00 [0.92-1.09] 0/29 0/113 0% improvement All studies 0% 1.00 [0.92-1.09] 0/29 0/113 0% improvement 1 remdesivir COVID-19 viral clearance result c19rmd.com May 2022 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.98 Favors remdesivir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gottlieb (DB RCT) 87% 0.13 [0.03-0.59] death/hosp. 2/279 15/283 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.0064 Early treatment 87% 0.13 [0.03-0.59] 2/279 15/283 87% improvement Wang (RCT) -9% 1.09 [0.54-2.18] death 22/158 10/78 Improvement, RR [CI] Treatment Control Spinner (RCT) 35% 0.65 [0.18-2.40] death 5/384 4/200 Beigel (RCT) 27% 0.73 [0.52-1.03] death 541 (n) 521 (n) SOLIDARITY (RCT) 5% 0.95 [0.81-1.11] death 301/2,743 303/2,708 Mahajan (RCT) -76% 1.76 [0.46-6.82] death 5/34 3/36 Barrat-Due (DB RCT) 0% 1.00 [0.20-4.60] death 3/37 4/53 Ader (RCT) 6% 0.94 [0.59-1.45] death 34/414 37/418 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.21 Late treatment 8% 0.92 [0.81-1.05] 370/4,311 361/4,014 8% improvement All studies 13% 0.87 [0.69-1.09] 372/4,590 376/4,297 13% improvement 8 remdesivir COVID-19 Randomized Controlled Trials c19rmd.com May 2022 Tau​2​ = 0.03, I​2​ = 30.9%, p = 0.22 Effect extraction pre-specified(most serious outcome) Favors remdesivir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wang (RCT) -9% 1.09 [0.54-2.18] 22/158 10/78 Improvement, RR [CI] Treatment Control Spinner (RCT) 35% 0.65 [0.18-2.40] 5/384 4/200 Beigel (RCT) 27% 0.73 [0.52-1.03] 541 (n) 521 (n) SOLIDARITY (RCT) 5% 0.95 [0.81-1.11] 301/2,743 303/2,708 Mahajan (RCT) -76% 1.76 [0.46-6.82] 5/34 3/36 Barrat-Due (DB RCT) 0% 1.00 [0.20-4.60] 3/37 4/53 Ader (RCT) 6% 0.94 [0.59-1.45] 34/414 37/418 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.21 Late treatment 8% 0.92 [0.81-1.05] 370/4,311 361/4,014 8% improvement All studies 8% 0.92 [0.81-1.05] 370/4,311 361/4,014 8% improvement 7 remdesivir COVID-19 RCT mortality results c19rmd.com May 2022 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.21 Favors remdesivir Favors control